as 12-18-2024 3:37pm EST
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
Founded: | 2010 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 6.7M | IPO Year: | N/A |
Target Price: | $126.50 | AVG Volume (30 days): | 2.7M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.05 | EPS Growth: | N/A |
52 Week Low/High: | $2.00 - $20.60 | Next Earning Date: | 11-15-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
PPBT Breaking Stock News: Dive into PPBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
GlobeNewswire
15 days ago
GlobeNewswire
16 days ago
GlobeNewswire
a month ago
TipRanks
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
TipRanks
2 months ago
The information presented on this page, "PPBT Purple Biotech Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.